

In the Abstract:

~~The transdermal~~ Transdermal pharmaceutical preparations for the treatment of Parkinson's disease ~~contain~~ containing a combination of at least two active substances selected from the following groups of active substances: dopamine agonists and L-dopa, monoamine oxidase inhibitors, anticholinergics, NMDA-receptor antagonists, sympathomimetics; at least two of the said active substances being members of different active substance groups.